{'fraction_non_alphanumeric': 0.023109243697478993, 'fraction_numerical': 0.018907563025210083, 'mean_word_length': 5.311258278145695, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Histopathological evaluation of transarterial one shot infusion of adriamycin as a preoperative adjuvant chemotherapy for the breast cancer].

Thirty patients with resectable breast cancer were treated with transarterial one shot infusion of 20 mg of adriamycin as a preoperative adjuvant chemotherapy. After breast angiography by Seldinger's method, adriamycin at a dose of 20 mg was administered through the feeding artery with one shot injection. Anticancer effect of adriamycin was evaluated microscopically after radical mastectomy. In the primary tumor, the effective histological changes were found in 9 (30%) of 30 cases. In the metastatic lymph nodes, the effective changes were found in 5 (50%) of 10 cases. Mild side effects were seen in 70% of the cases, but not serious. It was suggested that transarterial one shot infusion of 20 mg adriamycin was a histopathologically effective procedure as preoperative chemotherapy for breast cancer.